Lisata Therapeutics Inc. (LSTA NASDAQ) stock market data APIs
$2.1045
0.06(2.9%)
as of September 15, 2025
Try our APIs with
free plan!
Lisata Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Prev. Close
2.1045
Open
2.1685
High
2.2842
Low
2.1045
52 wk Range
1.87-4.2
Market Cap
19 176 K
Shares Outstanding
8 756 K
Revenue
1 070 K
EPS
-0.54
Beta
1.013
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Lisata Therapeutics Inc. data using free add-ons & libraries
Get Lisata Therapeutics Inc. Fundamental Data
Lisata Therapeutics Inc. Fundamental data includes:
- Net Revenue: 1 070 K
- EBITDA: -20 831 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.64
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Lisata Therapeutics Inc. News
New
Lisata extends cash runway into Q4 2026 while advancing certepetide development milestones
Earnings Call Insights: Lisata Therapeutics (LSTA) Q2 2025 MANAGEMENT VIEW * David J. Mazzo, President and CEO, reported that Lisata executed on several clinical and corporate milestones, includin...
Lisata Secures New Composition of Matter Patent for Certepetide
By Daniella Parra Lisata Therapeutics said it has been granted a new composition of matter patent for its lead drug candidate, certepetide, offering the highest level of IP protection by covering the...
Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update
BASKING RIDGE, N.J. and SUBIACO, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company de...
Lisata Therapeutics stock price target raised to $32 from $20 at Brookline
Investing.com - Brookline Capital Markets raised its price target on Lisata Therapeutics, Inc (NASDAQ:LSTA) to $32.00 from $20.00 while maintaining a Buy rating. Currently trading at $2.75, the compan...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
